替比夫定联合扶正化瘀片治疗慢性乙型肝炎肝纤维化60例疗效观察

董小平

doi:10.3969/j.issn.1001-5256.2013.09.014

替比夫定联合扶正化瘀片治疗慢性乙型肝炎肝纤维化60例疗效观察

DOI: 10.3969/j.issn.1001-5256.2013.09.014

董小平

郑州市第六人民医院

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2568
- HTML全文浏览量: 15
- PDF下载量: 628
- 被引次数: 0
出版历程
- 收稿日期: 2013-01-02
- 出版日期: 2013-09-20

Therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in treatment of liver fibrosis in chronic hepatitis B: a report of 60 cases

Dong XiaoPing

The Sixth People's Hospital of Zhengzhou City

摘要

摘要: 目的探讨替比夫定片联合扶正化瘀片治疗慢性乙型肝炎肝纤维化的疗效。方法选择本院2011年7月至2012年11月收治的慢性乙型肝炎（CHB）患者120名,随机分为2组,治疗组与对照组各60例。治疗组和对照组常规应用替比夫定片抗病毒及护肝等治疗;治疗组在上述治疗同时,联合应用扶正化瘀片治疗6个月。观测肝功能、肝纤维化四项指标、患者的症状体征等变化。计数资料采用χ2检验,计量资料采用t检验。结果经过6个月治疗,治疗组AST（33.1±15.5 vs 39.5±18.4）、白蛋白/球蛋白比例（A/G）（1.78±0.41 vs 1.64±0.32）、TBil（13.8±6.6 vs 17.9±8.3）复常,ALT（55.3±23.4 vs 64.7±27.6）降低,与对照组比较差异皆有统计学意义（t值分别为2.060、2.085、3.172、2.012,P值均<0.05）;治疗组血清透明质酸（HA）（107.7±82.3 vs141.6±91.4）、层黏连蛋白（LN）（125.4±73.2 vs 154.9±76.5）、Ⅲ型前胶原（PⅢP）（0.61±0.56 vs 0.96±0.44）、...
- 替比夫定 /
- 扶正化瘀片 /
- 肝炎,乙型,慢性 /
- 肝硬化
Abstract: Objective To investigate the therapeutic effect of telbivudine combined with Fuzheng Huayu tablets in the treatment of liver fibrosis in chronic hepatitis B ( CHB) . Methods A total of 120 patients with CHB, who were admitted to our hospital from July 2011 to November 2012, were randomly divided into treatment group ( n = 60) and control group ( n = 60) . All patients received antiviral and liver-protecting therapy with telbivudine; meanwhile, the treatment group was given Fuzheng Huayu tablets as an addition for 6 months. The liver function, four indices for liver fibrosis, and patient' s symptoms and signs were evaluated. The enumeration data were analyzed by chi-square test, and the measurement data were analyzed by t- test. Results After 6 months of treatment, the treatment group showed normalized aspartate aminotransferase ( AST) , albumin / globulin ratio ( A / G) , and total bilirubin ( TBil) as well as decreased alanine aminotransferase ( ALT) , and there were significant differences between the treatment group and control group in AST ( 33. 1 ± 15. 5 vs 39. 5 ± 18. 4, t = 2. 060, P < 0. 05) , A / G ( 1. 78 ± 0. 41 vs 1. 64 ± 0. 32, t = 2. 085, P < 0. 05) , TBil ( 13. 8 ± 6. 6 vs 17. 9 ± 8. 3, t = 3. 172, P <0. 05) , and ALT ( 55. 3 ± 23. 4 vs 64. 7 ± 27. 6, t = 2. 012, P < 0. 05) ; also, the treatment group showed significant improvements in hyaluronic acid ( HA) , laminin ( LN) , type Ⅲ procollagen peptide ( PⅢP) , and type Ⅳ collagen ( Ⅳ- C) , and there were significant differences between the treatment group and control group in HA ( 107. 7 ± 82. 3 vs 141. 6 ± 91. 4, t = 2. 155, P < 0. 05) , LN ( 125. 4 ± 73. 2 vs154. 9 ± 76. 5, t = 2. 135, P < 0. 05) , PⅢP ( 0. 61 ± 0. 56 vs 0. 96 ± 0. 44, t = 3. 266, P < 0. 05) , and IV- C ( 90. 6 ± 78. 3 vs 134. 3 ±67. 9, t = 3. 807, P < 0. 05) . In addition, the treatment group had alleviated lassitude, improved appetite, and palliated abdominal distension, demonstrating significant differences compared with the control group ( 71. 7% vs 53. 3%, P < 0. 05; 83. 3% vs 65. 0%, P < 0. 05;80. 0% vs 58. 3%, P < 0. 05) . Conclusion When used along with Fuzheng Huayu tablets, telbivudine has better performances in relieving symptoms, improving liver function, and reducing liver fibrosis in CHB patients with liver fibrosis.
- telbivudine /
- FUZHENG HUAYU TABLET /
- hepatitis B, chronic /
- liver cirrhosis

HTML全文

参考文献(9)

[1]ZHONG W, XIE WF.New strategy for the treatment of hepatic fibrosis[J].J Clin Hepatol, 2011, 27 (3) :233-235. (in Chinese) 钟巍, 谢渭芬.肝纤维化治疗新策略[J].临床肝胆病杂志, 2011, 27 (3) :233-235.

[2]FANG Q, AI L, LIU YK.Observation of clinical effect and safety evaluation of a 48 week trial of Telbivudine in patients with chronic hepatitis B of hepatitis B e antigen-positive[J].China Med Herald, 2012, 9 (9) :89-91. (in Chinese) 方清, 艾丽, 刘幼昆.替比夫定治疗乙型肝炎e抗原阳性慢性乙型肝炎48周疗效观察和安全性评价[J].中国医药导报, 2012, 9 (9) :89-91.

[3]LUO SQ.Recent advance of telbivudine for the treatment of chronic hepatitis B[J].Chin J New Drugs, 2008, 17 (18) :626-629. (in Chinese) 罗生强.替比夫定治疗慢性乙型肝炎的新进展[J].中国新药杂志, 2008, 17 (18) :626-629.

[4]LIU Y, LIU P, LIU CH.Proteomic analysis of proliferation and apoptosis in carbon tetrachloride induced rat liver fibrosis[J].Chin J Hepatol, 2005, 13 (8) :563-567. (in Chinese) 刘莺, 刘平, 刘成海.细胞增殖与凋亡相关蛋白质在大鼠肝纤维化形成与消减中的动态变化[J].中华肝脏病杂志, 2005, 13 (8) :563-567.

[5]LIU CH, HU YY, XU LM, et al.Effect of Fuzhenghuayu formula and its action against liver fibrosis[J].China J Chin Mater Med, 2009, 11 (4) :12-22. (in Chinese) 刘成海, 胡义扬, 徐列明, 等.扶正化瘀方抗肝纤维化的作用和影响[J].中国中药杂志, 2009, 11 (4) :12-22.

[6]WANG QL, TAO YY, SHEN L, et al.Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-β1 Smads signaling pathway[J].J Chin Integr Med, 2012, 10 (5) :561-569. (in Chinese) 王清兰, 陶艳艳, 沈丽, 等.扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J].中西医结合学报, 2012, 10 (5) :561-569.

[7]ZHAO WL, CHENG H, YANG ZM.Effects of combination therapy of matrine with adefovir dipivoxil on hepatic fibrosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2011, 27 (5) :490-492. (in Chinese) 赵文莉, 程红, 杨忠民.阿德福韦酯联合苦参素治疗慢性乙型肝炎患者对肝纤维化指标的影响[J].临床肝胆病杂志, 2011, 27 (5) :490-492.

[8]LIU P.Prevention and treatment of hepatic fibrosis[J].Chin J Hepatol, 2000, 8 (4) :242. (in Chinese) 刘平.肝纤维化的防治[J].中华肝脏病杂志, 2000, 8 (4) :242.

[9]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment of chronic hepatitis B[J].J Clin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分会、中华医学会、感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.

施引文献

资源附件(0)

访问统计